Cancer Care Delivery Research Portfolio

CTAC July 12, 2017

Ann M. Geiger, MPH, PhD
Deputy Associate Director, Healthcare Delivery Research Program

Lead Scientist, NCORP Cancer Care Delivery




Outline

- Policy challenges effecting the delivery of cancer care and clinical research
- Role of the DCCPS Healthcare Delivery Research Program in supporting research to address these challenges and improve cancer care
- Use of NCORP as a vehicle for cancer care delivery research

How best to engage clinicians and clinical/translational researchers in advancing new area of cancer care delivery research?

Policy Challenges

Cumulative Increases in Health Insurance Premiums, Workers' Contributions to Premiums, Inflation, and Workers' Earnings, 1999-2016



SOURCE: Kaiser/HRET Survey of Employer-Sponsored Health Benefits, 1999-2016. Bureau of Labor Statistics, Consumer Price Index, U.S. City Average of Annual Inflation (April to April), 1999-2016; Bureau of Labor Statistics, Seasonally Adjusted Data from the Current Employment Statistics Survey, 1999-2016 (April to April).



Cancer Care Delivery is Changing

Historical state

Evolving future state

Public and Private sectors

Key characteristics

- Focus on clinical outcomes
- Fewer treatment options

Reimbursement

Fee-for-service

Key characteristics

- Focus on patient-centered outcomes
- Coordination of multiple treatments
- Aging population
- Survivor care

Reimbursement

Value- and episode-based

Accompanied by declining research funding and shifts in trial design

Potential Changes to Affordable Care Act

- Retain
 - Coverage on parental insurance up to age 26
 - Coverage for 10 essential benefits
 - Most Medicare provisions
- Modify
 - Subsidies for insurance premiums
 - Required coverage for individuals with pre-existing conditions
- Repeal
 - Employer mandate and small business subsidies
 - Individual mandate (add penalties for breaks in coverage)
- Phase out enhanced funding for Medicaid, with shift to block grants and expanded state flexibility (and innovation funds)

http://www.kff.org/interactive/proposals-to-replace-the-affordable-care-act/ (July 5, 2017)



Oncology Care Model

- Model Objective: Provide beneficiaries with improved care coordination to improve quality and decrease cost
- Test from July 1, 2016, through June 30, 2021
 - > 195 practices
 - ➤ 3,200+ oncologists
 - > 155,000+ beneficiaries
 - \$6 billion in reimbursements
 - 16 payers
- Episode = treatment and related care during 6 months after initiation of chemotherapy
 - Usual FFS payment plus two-part financial incentive with \$160 pbpm payment and potential for performance-based payment
 - Institute robust quality measurement
 - Provide enhanced services to improve care and decrease cost

Enhanced Service Requirements

- 1) Patient navigation
- 2) Care plan with 13 components based on IOM Care Management Plan
- **3)** 24/7 access to clinician with real-time access to medical records
- **4)** Use of therapies consistent with national guidelines
- **5)** Data-driven continuous quality improvement
- **6)** Use of certified EHR technology

EVALUATION DESIGN

- Mixed methods design: qualitative & quantitative
- Goals of the evaluation: measure impact of OCM on Medicare fee-for-service beneficiaries
 - Quality, health outcomes, costs of care, and patients' experiences with care
 - Compare changes over time in the participating oncology practices with changes in carefully selected/matched comparison practices
- CMS has contracted with a team of independent researchers to evaluate OCM
 - Abt Associates (prime)
 - Researchers from Harvard Medical School, The Lewin Group, and General Dynamics Information Technology
 - Oncology clinical consultants




Would OCM Data be Useful in Trials Context?

- Current CMS data potentially useful to
 - Conduct long-term follow-up for health conditions requiring medical treatment
 - Estimate direct costs of health care utilization
 - Assess representativeness of trial enrollees
- ullet OCM evaluation data unlikely to add value ($oldsymbol{i} oldsymbol{f}$ available)
 - Small number of people in both trials and OCM practice
 - Follow-up ends within months of treatment cessation
 - Available data focused on limited number of quality metrics

Healthcare Delivery Research Program Division of Cancer Control and Population Sciences

HEALTHCARE DELIVERY RESEARCH PROGRAM

Advancing innovative research to improve the delivery of cancer-related care





Grant Portfolio - Examples

- Lung Cancer Screening Participation & Nodule Management
- Reducing Diagnostic Error in Melanoma and Breast & Lung Cancer
- Utilizing EHR to Measure & Improve Prostate Cancer Care*
- Care Coordination for Complex Cancer Survivors*
- Influence of Hospital Variability on Management of Cancer Treatment Complications*
- Technology Diffusion in Cancer: Variation, Outcomes, and Cost
- Assessing Cancer Care after Insurance Expansions*

^{*}New investigators




Funding Opportunity Announcements


- Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake
- Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults
- Surgical Disparities Research
- Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery
- Intervening with Cancer Caregivers to Improve Patient & Caregiver
 Health Outcomes & Optimize Healthcare Utilization
- End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses

21st Century Cures Act / Beau Biden Cancer Moonshot: Minimize cancer treatment's debilitating side effects

- Accelerate adoption of technology-aided systems that:
 - gather and monitor patient-reported symptoms
 - provide actionable decision support approaches utilizing evidence-based guidelines to treat symptoms throughout the cancer continuum.



Financial Toxicity Research Questions: What, Why, and How Intervene?




Altice CK et al. J Natl Cancer Inst. 2017.

Zafar SY. J Natl Cancer Inst. 2016.

NCORP Cancer Care Delivery Research

PRACTICE TRANSFORMATION!



Erin E. Kent et al. JCO 2015;33:2705-2711

CCDR Concepts Awaiting Protocols (as of 6/5/17)

Research Base/Study Title	Study Design
ECOG-ACRIN – Longitudinal Assessment of	Observational
Financial Burden in Patients with Colon or	Patients
Rectal Cancer Treated with Curative Intent	
ECOG-ACRIN – Biomarker Testing in	Observational
Common Solid Cancers: A Survey of Current	Practices
Practices in Precision Oncology in the	
Community Setting	
Alliance – Improving Surgical Care and	Cluster randomized trial
Outcomes in Older Cancer Patients through	Patients and practices
Implementation of an Efficient Pre-Surgical	
Toolkit (OPTI-Surg)	
Alliance – Assessing Financial Toxicity in	Observational
Patients with Blood Cancers	Patients and practices

CCDR Protocols Pending Activation (as of 6/5/17)

Research Base/Study Title	Study Design
Alliance - Testing Decision Aids to Improve	Cluster-randomized trial
Prostate Cancer Decisions for Minority Men	Patients and practices

CCDR Protocols in Review (as of 6/5/17)

Research Base/Study Title	Study Design
COG - Documentation and Delivery of Guideline-Consistent Treatment in AYA Acute Lymphoblastic Leukemia	Observational Patients and clinicians/staff
Wake Forest - Implementation of Smoking Cessation Services within NCORP Community Sites	Cluster randomized trial Patients and facilities
Wake Forest - A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors	Individually randomized trial Patients

Open CCDR Studies (as of 6/5/17)


Research Base/Study Title	Study Design
SWOG - Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer	Observational Patients/caregivers
SWOG - A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention (TRACER)	Cluster randomized trial Patients & practices
COG - Improving the Use of Evidence-Based Supportive Care Clinical Practice Guidelines in Pediatric Oncology	Observational Patients & clinicians

Future Research Directions (Steering Committee, June 12, 2017)

- Care coordination between
 - Specialists and primary care
 - Academic and community institutions
- Practice change
 - Clinician behavior
 - Use of technology
 - Decision aids
 - Patient-reported outcomes

How best to engage clinicians and clinical/translational researchers in advancing new area of cancer care delivery research?

PRACTICE TRANSFORMATION!



Erin E. Kent et al. JCO 2015;33:2705-2711

Thank you.